Vimian Group AB (publ) (VIMGF)
USD 3.62
(0.0%)
USD 3.62
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 188.15 Million EUR | 25.11% |
| 2022 | 148.75 Million USD | 53.16% |
| 2021 | 97.12 Million USD | 169.12% |
| 2020 | 36.09 Million USD | 152.8% |
| 2019 | 14.27 Million USD | 196.12% |
| 2018 | 4.82 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 51.12 Million USD | 0.37% |
| 2024 Q2 | 50.94 Million USD | 2.14% |
| 2024 Q1 | 49.87 Million EUR | -6.52% |
| 2023 FY | 186.11 Million USD | 25.11% |
| 2023 Q2 | 46.42 Million USD | 9.59% |
| 2023 Q1 | 42.35 Million USD | 22.51% |
| 2023 Q3 | 43.98 Million USD | -5.25% |
| 2023 Q4 | 53.35 Million USD | 21.3% |
| 2022 Q3 | 39.89 Million USD | 2.28% |
| 2022 FY | 148.75 Million USD | 53.16% |
| 2022 Q4 | 34.57 Million USD | -13.33% |
| 2022 Q2 | 39 Million EUR | 10.53% |
| 2022 Q1 | 35.28 Million EUR | 34.66% |
| 2021 FY | 97.12 Million USD | 169.12% |
| 2021 Q3 | 24.46 Million EUR | -6.54% |
| 2021 Q4 | 26.2 Million EUR | 7.11% |
| 2021 Q2 | 26.17 Million EUR | 29.04% |
| 2021 Q1 | 20.28 Million EUR | -62.4% |
| 2020 Q4 | 53.95 Million EUR | 456.6% |
| 2020 FY | 36.09 Million USD | 152.8% |
| 2020 Q2 | 9.62 Million EUR | 41.45% |
| 2020 Q1 | 6.8 Million EUR | 0.0% |
| 2020 Q3 | 9.69 Million EUR | 0.73% |
| 2019 FY | 14.27 Million USD | 196.12% |
| 2018 FY | 4.82 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -17836.606% |
| Arrayit Corporation | 6.19 Million USD | -2935.945% |
| Atlantic International Corp. | 5.57 Million USD | -3272.996% |
| Biocept, Inc. | 29.4 Million USD | -539.961% |
| Bioqual, Inc. | 7.44 Million USD | -2425.987% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -24267.927% |
| DermTech, Inc. | 104.01 Million USD | -80.892% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | -13.005% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | -731.673% |
| iMD Companies, Inc. | 151.8 Thousand USD | -123841.927% |
| IDenta Corp. | 662.97 Thousand USD | -28280.407% |
| Interpace Biosciences, Inc. | 20.23 Million USD | -829.987% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -483825.311% |
| InVitro International | 661.32 Thousand USD | -28351.258% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | -2550.817% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -323679.942% |
| Medical Imaging Corp. | 1.91 Million USD | -9739.899% |
| NovelStem International Corp. | 3.53 Million USD | -5218.42% |
| Optigenex Inc. | 1.28 Million USD | -14509.793% |
| PharmChem, Inc. | 2.93 Million USD | -6318.98% |
| Proteome Sciences plc | 3.26 Million USD | -5657.497% |
| Response Genetics, Inc | 25.31 Million USD | -643.138% |
| Rennova Health, Inc. | 7.67 Million USD | -2350.642% |
| RushNet, Inc. | 1.78 Million USD | -10415.447% |
| ScreenPro Security Inc. | 3.23 Million USD | -5709.202% |
| Stella Diagnostics Inc. | 11.42 Million USD | -1546.59% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | -2462.367% |
| Todos Medical Ltd. | 14.05 Million USD | -1238.419% |